ǂa ǂretrospective analysis from an early access program
Oliver Illini (Avtor), Hannah Fabikan (Avtor), Aurélie Swalduz (Avtor), Anders Vikström (Avtor), Dagmar Krenbek (Avtor), Michael Schumacher (Avtor), Maximilian J Hochmair (Avtor), Elizabeth Dudnik (Avtor), Michael Studnicka (Avtor), Ronny Öhman (Avtor), Robert Wurm (Avtor), Tanja Čufer (Avtor), Katja Mohorčič (Avtor)

Povzetek

Background: Patients with non-small cell lung cancer (NSCLC) presenting with mesenchymal–epithelial transition (MET) exon 14 skipping mutation have an unfavorable prognosis with standard treatments. Capmatinib is a selective MET inhibitor, which showed promising efficacy in this patient population in early trials. Methods: We performed a retrospective, international, multicenter efficacy and safety analysis in patients with NSCLC treated with capmatinib in an early access program between March 2019 and December 2021. Results: Data from 81 patients with advanced MET exon 14 mutated NSCLC treated with capmatinib in first- or later-line therapy were analyzed. Median age was 77years (range, 48–91), 56% were women, 86% had stage IV disease, and 27% had brain metastases. For all patients, the objective response rate (ORR) to capmatinib was 58% (95% CI, 47–69), whereas it was 68% (95% CI, 50–82) in treatment-naïve and 50% (95% CI, 35–65) in pretreated patients. The median progression-free survival was 9.5months (95% CI, 4.7–14.3), whereas it was 10.6months (95% CI, 5.5–15.7) in first-line and 9.1months (95% CI, 3.1–15.1) in pretreated patients. After a median follow-up of 11.0months, the median overall survival was 18.2 months (95% CI, 13.2–23.1). In patients with measurable brain metastases (n=11), the intracranial ORR was 46% (95% CI, 17–77). Capmatinib showed a manageable safety profile. Grade⩾3 treatment-related adverse events included peripheral edema (13%), elevated creatinine (4%), and elevated liver enzymes (3%). Conclusion: In patients with MET exon 14 skipping mutation, capmatinib showed durable systemic and intracranial efficacy and a manageable safety profile. This analysis confirms previously reported phase II data in a real-world setting.

Ključne besede

podatki iz resničnega življenja;capmatinib;tarčna terapija;real-world data;targeted therapy;

Podatki

Jezik: Angleški jezik
Leto izida:
Tipologija: 1.01 - Izvirni znanstveni članek
Založnik: Sage Publications
UDK: 616-006
COBISS: 112187139 Povezava se bo odprla v novem oknu
ISSN: 1758-8359
Št. ogledov: 76
Št. prenosov: 76
Ocena: 0 (0 glasov)
Metapodatki: JSON JSON-RDF JSON-LD TURTLE N-TRIPLES XML RDFA MICRODATA DC-XML DC-RDF RDF

Ostali podatki

Sekundarne ključne besede: Carcinoma, non-small cell lung;Drug therapy;Genetics;Molecular targeted therapy;Nedrobnocelični karcinom pljuč;Terapija z zdravili;Genetika;Molekularna tarčna terapija;
Komentar vira: Nasl. z nasl. zaslona; Soavtorici iz Slovenije: Katja Mohorčič, Tanja Čufer; Opis vira z dne 20. 6. 2022;
Strani: str. 1-22
Zvezek: ǂVol. ǂ14
Čas izdaje: Jan./Dec. 2022
DOI: 10.1177/17588359221103206
ID: 15730078